SR ONE CAPITAL MANAGEMENT, LP Long-Term Concentrated

CIK: 0001910264 · Show all filings

Period: Q3 2023 (← Previous) (Next →)

Filing Date: Nov 13, 2023

Total Value ($000): $195,121 (100.0% shares, 0.0% debt)

Holdings (6)

ACLX ARCELLX INC. 72.6%

Value ($000) $141,605 Shares 3,946,630 Est. Cost $16.72 Unrealized +106.2%

MLYS MINERALYS THERAPEUTICS 8.7%

Value ($000) $17,067 Shares 1,794,600 Est. Cost $16.83 Unrealized -22.5%

DSGN DESIGN THERAPEUTICS INC 7.9%

Value ($000) $15,402 Shares 6,526,476 Est. Cost $16.67 Unrealized -72.0%

SPRY ARS PHARMACEUTICALS 7.8%

Value ($000) $15,169 Shares 4,012,903 Est. Cost $6.79 Unrealized -3.3%

— EFFECTOR THERAPEUTICS INC 2.1%

Value ($000) $4,025 Shares 6,822,114 Est. Cost $8.28 Unrealized —

NKTX NKARTA INC. 0.9%

Value ($000) $1,853 Shares 1,333,333 Est. Cost $13.12 Unrealized -85.5%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
ACLX	ARCELLX INC.	3,946,630	$141,605	72.6%	$16.72	+106.2%	COMMON STOCK	03940C100
MLYS	MINERALYS THERAPEUTICS	1,794,600	$17,067	8.7%	$16.83	-22.5%	COM	603170101
DSGN	DESIGN THERAPEUTICS INC	6,526,476	$15,402	7.9%	$16.67	-72.0%	COM	25056L103
SPRY	ARS PHARMACEUTICALS	4,012,903	$15,169	7.8%	$6.79	-3.3%	COM	82835W108
—	EFFECTOR THERAPEUTICS INC	6,822,114	$4,025	2.1%	$8.28	—	COM	28202V108
NKTX	NKARTA INC.	1,333,333	$1,853	0.9%	$13.12	-85.5%	COM	65487U108